FDA official sees some delays over safety
SILVER SPRING, Maryland (Reuters) - A new focus on drug safety is delaying the approval of some medicines as regulators impose requirements meant to minimize side effects, a top U.S. drug regulator told Reuters on Tuesday.
<p><img src="http://feeds.reuters.com/~a/reuters/healthNews?i=tQetvm" border="0"></img> (http://feeds.reuters.com/~a/reuters/healthNews?a=tQetvm)</p><div class="feedflare">
<img src="http://feeds.reuters.com/~f/reuters/healthNews?i=e58CEH" border="0"></img> (http://feeds.reuters.com/~f/reuters/healthNews?a=e58CEH) <img src="http://feeds.reuters.com/~f/reuters/healthNews?i=DLsMWh" border="0"></img> (http://feeds.reuters.com/~f/reuters/healthNews?a=DLsMWh) <img src="http://feeds.reuters.com/~f/reuters/healthNews?i=NLq4xh" border="0"></img> (http://feeds.reuters.com/~f/reuters/healthNews?a=NLq4xh)
</div><img src="http://feeds.reuters.com/~r/reuters/healthNews/~4/299316839" height="1" width="1"/>
http://feeds.reuters.com/~r/reuters/healthNews/~3/299316839/idUSTON77285320080527